Cargando…

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs

Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt(IV)(N(1))(N(2))(L(1))(L(2))(A(1))(A(2))], where N(1) and N(2) are non-leaving nitrogen donor ligands, L(1) and L(2) are leaving ligands, and A(1) and A(2) are axial ligands, have attracted increasing attention due to their promisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jingjing, Ding, Weize, Zhu, Xingfan, Li, Bingbing, Zeng, Fangang, Wu, Kui, Wu, Xiaoqin, Wang, Fuyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218644/
https://www.ncbi.nlm.nih.gov/pubmed/35755267
http://dx.doi.org/10.3389/fchem.2022.876410
_version_ 1784731934532829184
author Huang, Jingjing
Ding, Weize
Zhu, Xingfan
Li, Bingbing
Zeng, Fangang
Wu, Kui
Wu, Xiaoqin
Wang, Fuyi
author_facet Huang, Jingjing
Ding, Weize
Zhu, Xingfan
Li, Bingbing
Zeng, Fangang
Wu, Kui
Wu, Xiaoqin
Wang, Fuyi
author_sort Huang, Jingjing
collection PubMed
description Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt(IV)(N(1))(N(2))(L(1))(L(2))(A(1))(A(2))], where N(1) and N(2) are non-leaving nitrogen donor ligands, L(1) and L(2) are leaving ligands, and A(1) and A(2) are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs.
format Online
Article
Text
id pubmed-9218644
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92186442022-06-24 Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs Huang, Jingjing Ding, Weize Zhu, Xingfan Li, Bingbing Zeng, Fangang Wu, Kui Wu, Xiaoqin Wang, Fuyi Front Chem Chemistry Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt(IV)(N(1))(N(2))(L(1))(L(2))(A(1))(A(2))], where N(1) and N(2) are non-leaving nitrogen donor ligands, L(1) and L(2) are leaving ligands, and A(1) and A(2) are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs. Frontiers Media S.A. 2022-06-09 /pmc/articles/PMC9218644/ /pubmed/35755267 http://dx.doi.org/10.3389/fchem.2022.876410 Text en Copyright © 2022 Huang, Ding, Zhu, Li, Zeng, Wu, Wu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Huang, Jingjing
Ding, Weize
Zhu, Xingfan
Li, Bingbing
Zeng, Fangang
Wu, Kui
Wu, Xiaoqin
Wang, Fuyi
Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
title Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
title_full Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
title_fullStr Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
title_full_unstemmed Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
title_short Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
title_sort ligand evolution in the photoactivatable platinum(iv) anticancer prodrugs
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218644/
https://www.ncbi.nlm.nih.gov/pubmed/35755267
http://dx.doi.org/10.3389/fchem.2022.876410
work_keys_str_mv AT huangjingjing ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs
AT dingweize ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs
AT zhuxingfan ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs
AT libingbing ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs
AT zengfangang ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs
AT wukui ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs
AT wuxiaoqin ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs
AT wangfuyi ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs